Compare Google Inc (GOOG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs GSK plc — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: Google Inc is far larger — about 46.1× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and GSK plc for 93 Days on average.
| GOOG | GSK | |
|---|---|---|
Market Cap | $4.24T | $91.88B |
Volume | 13,937,902 | 7,730,529 |
Sector | Media | Health |
52-Week High | $399.06 | $61.18 |
52-Week Low | $237.49 | $43.24 |
Typical Hold Time | 137 Days | 93 Days |
Enterprise Value | $4.13T | $111.88B |
Dividend Yield | 0.26% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $344.86, down 0.72% today, with a bullish technical signal from moving averages and strong support near $342. The company reported robust Q2 2026 EPS of $9.11, beating expectations, with revenue growth accelerating to $402.84B in 2025. Analyst consensus is strongly bullish with an 87% buy rating and a $435.24 price target, though recent news highlights rising capital expenditures and potential free cash flow pressures.
Outlook remains positive driven by AI and cloud expansion, but risks include heightened spending, regulatory scrutiny, and class-action lawsuits. The stock's valuation at a P/E of 17.3 appears reasonable given high profitability margins, positioning it for long-term growth if execution continues.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
